Exagen Q3 2023 Gaap EPS $(0.31) Beats $(0.46) Estimate, Sales $13.42M Beat $10.33M Estimate

Author: Benzinga Newsdesk | November 13, 2023 05:15pm
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 34.04 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $13.42 million which beat the analyst consensus estimate of $10.33 million by 29.87 percent. This is a 8.90 percent decrease over sales of $14.73 million the same period last year.

Posted In: XGN